Obsessional Symptoms Associated with Risperidone Treatment

1998 ◽  
Vol 32 (2) ◽  
pp. 299-301 ◽  
Author(s):  
Rathi Mahendran
Keyword(s):  
Side Effects ◽  
Antipsychotic Medication ◽  
Clinical Picture ◽  
Low Dose ◽  
Past History ◽  
Obsessive Compulsive ◽  
Obsessive Compulsive Symptoms ◽  
History Of ◽  
Risperidone Treatment

Objective: The aim of this paper is to report the occurrence of obsessional symptoms with risperidone treatment in a patient with no past history of obsessive-compulsive symptoms. Clinical picture: A 26–year-old, single, Chinese lady with a chronic untreated schizophrenic illness was prescribed risperidone after she experienced side effects with other antipsychotic medication. After the second week on risperidone, she developed obsessional symptoms. Treatment and Outcome: The obsessional symptoms responded to treatment with low dose clomipramine. Conclusion: The potential for the newer antipsychotic medication to precipitate or exacerbate obsessive-compulsive symptoms during treatment for schizophrenia must be borne in mind.

Obsessive—Compulsive Disorder in Post-Streptococcal Infection

1998 ◽  
Vol 32 (4) ◽  
pp. 579-581
Author(s):  
Erik Monasterio ◽  
Roger T. Mulder ◽  
Thomas D. Marshall
Keyword(s):  
Streptococcal Infection ◽  
Past History ◽  
Sudden Onset ◽  
Autoimmune Response ◽  
Progressive Reduction ◽  
Obsessive Compulsive ◽  
Obsessive Compulsive Symptoms ◽  
Compulsive Disorder ◽  
History Of ◽  
Peritoneal Infection

Objective: We describe the sudden onset of obsessive—compulsive symptoms fol lowing a peritoneal infection with α-haemolytic streptococci. Clinical picture: A 35–year-old woman with no past history or family history of obsessions or compulsions developed these symptoms 2 weeks after a peritoneal infection. Treatment: The patient received 80 mg fluoxetine daily. Outcome: She responded to treatment with a progressive reduction in symptoms. Conclusions: It is suggested that these obsessions and compulsions may be related to an autoimmune response to the streptococcal infection.

PROLACTIN IN CHILDHOOD OBSESSIVE-COMPULSIVE DISORDER: CLINICAL CORRELATES AND RESPONSE TO CLOMIPRAMINE

PEDIATRICS ◽  
1991 ◽  
Vol 88 (5) ◽  
pp. 992-992
Author(s):  
Gregory L. Hanna ◽  
James T. MCCracken ◽  
Dennis P. Cantwell
Keyword(s):  
Obsessive Compulsive Disorder ◽  
Obsessive Compulsive ◽  
Tic Disorder ◽  
Obsessive Compulsive Symptoms ◽  
Compulsive Disorder ◽  
Serotonergic Receptors ◽  
Duration Of Illness ◽  
Chronic Tic Disorder ◽  
History Of ◽  
Clomipramine Treatment

Basal prolactin concentrations were measured before treatment in 18 children and adolescents with obsessive-compulsive disorder as well as in 15 of these patients after 4 and 8 weeks of clomipramine treatment. Basal prolactin levels were influenced by a history of chronic tic disorder and by the duration and severity of obsessive-compulsive symptoms. Clomipramine administration significantly increased basal prolactin levels. A slight decline in prolactin levels during the last 4 weeks of clomipramine treatment was positively correlated with a favorable treatment response and negatively correlated with duration of illness. If the changes in prolactin levels observed during clomipramine treatment are due primarily to changes in serotonergic neurotransmission, these data suggest that clomipramine treatment of obsessive-compulsive disorder produces an adaptive decrease in the responsiveness of serotonergic receptors.

scholarly journals Psychotically driven aggression is associated with greater mentalizing challenges in psychotic spectrum disorders

2020 ◽  
Vol 20 (1) ◽  
Author(s):  
Anette GM Johansson ◽  
Malin Källman ◽  
Lennart Högman ◽  
Marianne Kristiansson ◽  
Håkan Fischer ◽  
...  
Keyword(s):  
Social Cognition ◽  
Antipsychotic Medication ◽  
Goal Attainment ◽  
Negative Symptoms ◽  
Past History ◽  
Intellectual Ability ◽  
Swedish Version ◽  
History Of ◽  
Spectrum Disorders ◽  
Matrix Reasoning

Abstract Background Some aggressive acts committed by individuals with psychotic spectrum disorders (PSD) are understandable in the context of interpersonal conflict or goal attainment, yet others are unpredictable, arising from delusions or hallucinations (psychotically driven aggressive acts, PDA). It is unknown if there are underlying differences in cognitive or perceptive social cognition in relation to aggression motivation in PSD. Method We compared differences in social cognition performance between 49 individuals with PSD who had committed PDA with those exhibiting other types of aggression (n = 31) (non-PDA) and to community controls (n = 81) on the Swedish version of Double Movie for the Assessment of Social Cognition – Multiple Choice (DMASC-MC). Participants with PSD had more than 3 months of clinical stability and substance use abstention and stable antipsychotic medication doses. General intellectual ability was assessed with the information and matrix reasoning subtests of the Wechsler Intelligence Scales. Results The PSD group with a history of PDA exhibited lower total and perceptive social cognition scores on the DMASC-MC than the non-PDA group and controls. In addition, they also showed lower cognitive scores compared to typical controls. Lower total scores were associated with lower scores on Wechsler intelligence subtests information and matrix reasoning. Taking this into account, the PDA group still had lower social cognition scores. There were no associations of antipsychotic medication dosages, positive or negative symptoms with social cognition scores. Higher antipsychotic dosage at the time of DMASC-MC testing and social cognition scores predicted a past history of PDA. Conclusions We conclude that impaired social cognition, particularly perceptive social cognition, is associated with PDA in individuals with PSD.

Low-dose oral contraception and blood pressure in women with a past history of elevated blood pressure

1985 ◽  
Vol 151 (1) ◽  
pp. 28-32 ◽  
Author(s):  
Charles C. Tsai ◽  
H.Oliver Williamson ◽  
Bonnie H. Kirkland ◽  
Judy O. Braun ◽  
Chan F. Lam
Keyword(s):  
Blood Pressure ◽  
Low Dose ◽  
Past History ◽  
Oral Contraception ◽  
Elevated Blood Pressure ◽  
Elevated Blood ◽  
Dose Oral ◽  
History Of

The Clinical Significance of Obsessions in Schizophrenia

1957 ◽  
Vol 103 (433) ◽  
pp. 773-785 ◽  
Author(s):  
Ismond Rosen
Keyword(s):  
Clinical Significance ◽  
Obsessive Compulsive ◽  
Prodromal Phase ◽  
Schizophrenic Psychosis ◽  
Obsessive Compulsive Symptoms ◽  
Obsessional Neurosis ◽  
The Family ◽  
History Of ◽  
Paranoid Schizophrenic

It is well known that obsessive-compulsive symptoms may occur in the prodromal phase or in the course of schizophrenia, and that schizophrenic symptoms may supervene in a long-standing obsessional neurosis. Stengel (1945) has reviewed much of the earlier literature concerning the relationships between obsessional neurosis and schizophrenia. The question whether obsessional neurosis could develop into schizophrenia has often been discussed. Pilcz (1922), Legewie (1923) and Schneider (1925) distinguished between genuine obsessions which were symptoms of an obsessional neurosis, and symptomatic obsessional ideas which could occur in various conditions. These authors, as well as Stekel (1950), doubted whether a genuine obsessional neurosis could develop into schizophrenia. Bleuler (1911) thought that some patients suffering with chronic obsessional symptoms were in fact schizophrenic, especially where a schizophrenic psychosis had been observed in the family. Mayer-Gross (1932) expressed the view that cases of obsessive-compulsive neurosis existing over decades without change and presenting marked autism were often schizophrenics. Together with Bleuler, Mayer-Gross suspected that many of Janet's “psychasthenic” patients had been schizophrenic. Janet (1903) had observed 3,000 cases of psychasthenia, of which 12 developed into psychosis, and two into hebephrenia, but Janet's psychasthenia probably included cases other than obsessional neurosis. There is a well-known case which showed how in the course of a long-standing obsessional neurosis, paranoid schizophrenic symptoms may make their appearance. This is the patient described by Freud (1918) in “The History of an Infantile Neurosis”, who, many years after he had been treated by Freud for obsessional symptoms, was treated for a paranoid state by Ruth Mack Brunswick (1928).

scholarly journals Efficacy of High-Dose and Low-Dose Simvastatin on Vascular Oxidative Stress and Neurological Outcomes in Patient with Acute Ischemic Stroke: A Randomized, Double-Blind, Parallel, Controlled Trial

2018 ◽  
Vol 2018 ◽  
pp. 1-6 ◽  
Author(s):  
Nattaphol Uransilp ◽  
Pannawat Chaiyawatthanananthn ◽  
Sombat Muengtaweepongsa
Keyword(s):  
Oxidative Stress ◽  
Ischemic Stroke ◽  
Acute Ischemic Stroke ◽  
Barthel Index ◽  
Low Dose ◽  
Past History ◽  
High Dose ◽  
Neurological Outcomes ◽  
History Of ◽  
Vascular Oxidative Stress

Backgrounds. Stroke is the leading cause of death and long-term disability. Oxidative stress is elevated during occurrence of acute ischemic stroke (AIS). Soluble LOX-1 (sLOX-1) and NO are used as biomarkers for vascular oxidative stress that can reflect stabilization of atherosclerotic plaque. Previous study showed that simvastatin can reduce oxidative stress and LOX-1 expression. Objectives. To evaluate neurological outcomes and serum sLOX-1 and NO levels in patients with AIS treatment with low dose 10 mg/day and high dose 40 mg/day of simvastatin. Methods. 65 patients with AIS within 24 hours after onset were randomized to treatment with simvastatin 10 mg/day or 40 mg/day for 90 days. Personal data and past history of all patients were recorded at baseline. The blood chemistries were measured by standard laboratory techniques. Serum sLOX-1 and NO levels and neurological outcomes including NIHSS, mRS, and Barthel index were tested at baseline and Day 90 after simvastatin therapy. Results. Baseline characteristics were not significantly different in both groups except history of hypertension. Serum sLOX-1 and NO levels significantly reduce in both groups (sLOX-1 = 1.19±0.47 and 0.98±0.37 ng/ml; NO = 49.28±7.21 and 46.59±9.36 μmol/l) in 10 mg/day and 40 mg/day simvastatin groups, respectively. Neurological outcomes including NIHSS, mRS, and Barthel index significantly improve in both groups. However, no difference in NO level and neurological outcomes was found at 90 days after treatment as compared between low dose 10 mg/day and high dose 40 mg/day of simvastatin. Conclusion. High-dose simvastatin might be helpful to reduce serum sLOX-1. But no difference in clinical outcomes was found between high- and low-dose simvastatin. Further more intensive clinical trial is needed to confirm the appropriate dosage of simvastatin in patients with acute ischemic stroke. This trial is registered with ClinicalTrials.gov ID: NCT03402204.

scholarly journals Should psychiatrists be more cautious about the long-term prophylactic use of antipsychotics?

2016 ◽  
Vol 209 (5) ◽  
pp. 361-365 ◽  
Author(s):  
Robin M. Murray ◽  
Diego Quattrone ◽  
Sridhar Natesan ◽  
Jim van Os ◽  
Merete Nordentoft ◽  
...  
Keyword(s):  
Side Effects ◽  
Physical Health ◽  
Antipsychotic Medication ◽  
Brain Structure ◽  
Low Dose ◽  
Cumulative Effects ◽  
Acute Episode ◽  
First Episode ◽  
Prophylactic Use

SummaryPatients who recover from an acute episode of psychosis are frequently prescribed prophylactic antipsychotics for many years, especially if they are diagnosed as having schizophrenia. However, there is a dearth of evidence concerning the long-term effectiveness of this practice, and growing concern over the cumulative effects of antipsychotics on physical health and brain structure. Although controversy remains concerning some of the data, the wise psychiatrist should regularly review the benefit to each patient of continuing prophylactic antipsychotics against the risk of side-effects and loss of effectiveness through the development of supersensitivity of the dopamine D2 receptor. Psychiatrists should work with their patients to slowly reduce the antipsychotic to the lowest dose that prevents the return of distressing symptoms. Up to 40% of those whose psychosis remits after a first episode should be able to achieve a good outcome in the long term either with no antipsychotic medication or with a very low dose.

Sign in / Sign up

Export Citation Format

Share Document